 | • レポートコード：B-MOR-040930 • 出版社/出版日：Mordor Intelligence / 2018年2月 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：医療・バイオ |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、バイオ医薬品の世界市場について調べ、バイオ医薬品の世界規模、市場動向、市場環境、製品・タイプ別（モノクローナル抗体、組換増殖因子、精製タンパク質、組換タンパク質、組換ホルモン、合成免疫調整剤、ワクチン、組換酵素、その他）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・バイオ医薬品の世界市場インサイト ・バイオ医薬品の世界市場環境 ・バイオ医薬品の世界市場動向 ・バイオ医薬品の世界市場規模 ・バイオ医薬品の世界市場規模：製品・タイプ別（モノクローナル抗体、組換増殖因子、精製タンパク質、組換タンパク質、組換ホルモン、合成免疫調整剤、ワクチン、組換酵素、その他） ・バイオ医薬品の世界市場：地域別市場規模・分析 ・バイオ医薬品の北米市場規模・予測 ・バイオ医薬品のアメリカ市場規模・予測 ・バイオ医薬品のヨーロッパ市場規模・予測 ・バイオ医薬品のアジア市場規模・予測 ・バイオ医薬品の日本市場規模・予測 ・バイオ医薬品の中国市場規模・予測 ・バイオ医薬品のインド市場規模・予測 ・バイオ医薬品の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global Biopharmaceuticals market has been estimated to reach USD 341.16 billion in 2023. The market is expected to register a CAGR of 8.5% during the forecast period 2018 to 2023. North America dominates the market due to the increasing technological advancements.
Increasing acceptance for biopharmaceuticals and huge market demand
Opportunities in biopharmaceuticals have been increasing over the past decade. The efficacy and the safety of the drugs are some of the key products features that drive the market growth. There have been biopharmaceutical products that are improving the quality of life and reducing the death rates in patients with HIV/AIDs, Cancer, Cystic fibrosis, rheumatoid arthritis. Biopharmaceuticals have reduced the number of deaths caused due to cancer and HIV/AIDS in the last decade. The efficacy of the drugs and the safety has increased the acceptance for biopharmaceuticals.
High-end manufacturing requirements
Unlike conventional pharmaceuticals, biopharmaceuticals are manufactured using living biological systems. Due to this, the biopharmaceutical manufacturing requires specialized equipment and devices like incubators that can support these biological systems. The cost of these devices and equipment is high as compared to regular manufacturing equipment. Along with this, most of the biopharmaceuticals require custom built manufacturing equipment and highly specialized personnel to operate them. Due to these high-end manufacturing requirements, the resources and time required to setup a biopharmaceutical manufacturing facility is very high which makes scaling really tough. So, these factors are acting as a restraint for Biopharmaceuticals market.
North America to Dominate the Market
The Biopharmaceuticals market is segmented by type of treatment and geography. By geography it is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa and South America.
North America dominates the Biopharmaceuticals market due to the increasing technological advancements and high investment & funding to support development of Biopharmaceuticals. Asia-Pacific is also expected to propel the Biopharmaceuticals market owing to factors, such as increasing accessibility to healthcare facilities in the region, and increasing economic growth.
Key developments in the market
• In January, 2018, GE Healthcare’s Flex Factory single-use bio manufacturing platform has been selected by Clover Biopharmaceuticals, a Chinese developer of biologics, for its new facility located in Changxing, Zhejiang.
• In January, 2018, Sandoz, a Novartis division and the global leader in biosimilars, announced a global partnership with Asia’s premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide.
Major key players: ABBVIE, AMGEN, BRISTOL – MYERS SQUIBB, ELI LILY & CO, JOHNSON & JOHNSON, MERCK & CO. INC, GLAXOSMITHKLINE PLC, ROCHE, PFIZER and NOVARTIS AG etc.
Reasons to purchase this report
• Market analysis for the Global Biopharmaceuticals Market, with region-specific assessments and competition analysis on a global and regional scale.
• Analyzing various perspectives of the company with the help of Porter’s five forces analysis
• The treatment type that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares and strategies employed by the major market players.
• 3 months analyst support along with the Market Estimate sheet in excel.
Customization of the report
• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.
レポート目次TABLE OF CONTENTS
1. INTRODUCTION
1.1 MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW
5.1 CURRENT MARKET SCENARIO
5.2 PORTER’S FIVE FORCES
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF CONSUMERS
5.2.3 THREATS OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES
5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY
6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
6.1 MARKET DRIVERS
6.1.1 INCREASING ACCEPTANCE FOR BIOPHARMACEUTICALS
6.1.2 HUGE MARKET DEMAND
6.2 MARKET RESTRAINTS
6.2.1 HIGH-END MANUFACTURING REQUIREMENTS
6.3 OPPORTUNITIES
6.4 KEY CHALLENGES
7. MARKET SEGMENTATION
7.1 GLOBAL BIOPHARMACEUTICALS MARKET, BY PRODUCT/TYPE
7.2 MONOCLONAL ANTIBODIES
7.2.1 ANTI-CANCER MONOCLONAL ANTIBODIES
7.2.2 ANTI-INFLAMMATORY MONOCLONAL ANTIBODIES
7.2.3 OTHER MONOCLONAL ANTIBODIES
7.3 RECOMBINANT GROWTH FACTORS
7.3.1 ERYTHROPOIETIN
7.3.2 GRANULOCYTE COLONY STIMULATING FACTOR
7.4 PURIFIED PROTEINS
7.4.1 LEUKEMIA INHIBITORY FACTOR (LIF)
7.4.2 P53 PROTEIN
7.4.3 P38 PROTEIN
7.5 RECOMBINANT PROTEINS
7.5.1 SERUM ALBUMIN
7.5.2 AMYLOID PROTEIN
7.5.3 DEFENSIN
7.5.4 CYCLASE
7.5.5 CASPASE
7.5.6 CATHEPSIN
7.6 RECOMBINANT HORMONES
7.6.1 RECOMBINANT HUMAN GROWTH HORMONE (HGH)
7.6.2 INSULIN
7.7 SYNTHETIC IMMUNOMODULATORS
7.8 VACCINES
7.8.1 RECOMBINANT VACCINES
7.8.1.1 CANCER VACCINES
7.8.1.2 MALARIA VACCINES
7.8.1.3 EBOLA VACCINE
7.8.1.4 HEPATITIS-B VACCINE
7.8.1.5 TETANUS VACCINE
7.8.1.6 DIPTHERIA VACCINE
7.8.1.7 CHOLERA VACCINE
7.8.2 CONVENTIONAL VACCINES
7.8.2.1 POLIO VACCINE
7.8.2.2 POX VACCINE
7.9 RECOMBINANT ENZYMES
7.9.1 ENTEROKINASE
7.9.2 TRANSFERRIN
7.10 OTHERS
7.10.1 BLOOD FACTORS
7.10.2 OTHERS
7.11 BY GEOGRAPHY
7.11.1 NORTH AMERICA
7.11.1.1 US
7.11.1.2 CANADA
7.11.1.3 MEXICO
7.11.2 EUROPE
7.11.2.1 FRANCE
7.11.2.2 UK
7.11.2.3 GERMANY
7.11.2.4 ITALY
7.11.2.5 SPAIN
7.11.2.6 REST OF EUROPE
7.11.3 ASIA-PACIFIC
7.11.3.1 INDIA
7.11.3.2 CHINA
7.11.3.3 JAPAN
7.11.3.4 AUSTRALIA
7.11.3.5 SOUTH KOREA
7.11.3.6 REST OF APAC
7.11.4 MIDDLE EAST AND AFRICA
7.11.4.1 GCC
7.11.4.2 SOUTH AFRICA
7.11.4.3 REST OF MIDDLE EAST AND AFRICA
7.11.5 SOUTH AMERICA
7.11.5.1 BRAZIL
7.11.5.2 ARGENTINA
7.11.5.3 REST OF SOUTH AMERICA
8. COMPETITIVE LANDSCAPE
8.1 MERGERS AND ACQUISITIONS
8.2 AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS
8.3 NEW PRODUCT LAUNCHES
9. KEY PLAYERS
9.1 ABBVIE
9.2 AMGEN
9.3 BRISTOL – MYERS SQUIBB
9.4 ELI LILY & CO
9.5 JOHNSON & JOHNSON
9.6 MERCK & CO. INC
9.7 NOVARTIS AG
9.8 PFIZER
9.9 GLAXOSMITHKLINE PLC
9.10 ROCHE HOLDING
9.11 OTHERS
10. FUTURE OUTLOOK OF THE MARKET